Introduction: The goal of organ transplantation is to provide durable organ function renal transplantation provides improved short- and long-term graft outcomes The long-term outcome of pediatric transplantation has improved over the last decade with an increase in the armamentarium of immunosuppressive agents and induction therapy reduce the frecuency of rejection and delayed graft function after transplantation and Induction therapies in kidney transplantation have led to prescriptions of lower doses of maintenance immunosuppression and fewer acute rejection episodes. Methods: We present our experience over the last four yr. Patients received TMG intraoperatively at a dose of 1.0 mg/kg/day for three a 5 days, According to criteria of high risk. The dose was decreased to 0.5 mg/kg/day or held dependent on the patient's WBC and platelet counts. Post-transplant immunosuppression also included corticosteroids, MMF, and either TAC or CSA. Patient and graft survival, number of acute rejection episodes, creatinine, were monitored during the follow-up period. Results: Twenty-eight renal transplants were performed in 28 pediatric patients ranging in age from 1 to 14 yr. 75% of patients received 1 to 3 doses of thymoglobulin induction and 25% received 4 to 7 doses for criteria of high risk. 27 patients received tacrolimus and 1 patient received ciclosporin A, either CSA or TAC was started when the creatinine was less 2mgdl, mean TAC serum trough levels at 1,3,6 and 12 months are shown in table (1). Three (10, 7%) rejection episodes occurred within the first year after transplantation, two for administration medication generic and one teenage not adherence. Patient and graft survival at two yr were 92% and 85%respectively. The post transplant survival is markedly lower for infants < 24 months receiving a deceased donor graft as it is the case in our data with 1 death. Four patients had graft loss in the first week after transplantation from primary infecction(2) and technical failure/thrombosis(2). Graft losses occurred in one additional patient during the time of follow-up with the loss occurring at 35 months due to complications of The urinary system.88 % to the patients had creatinine less 1,5mgdl at 24 months postrasplant Mean HLA -A,B mismatch was 53,6 and 60,7respectively and HLA DR mismatch was 3,3. Total HLA mismatch was 42.9. Twenty -four of the patients had immediate graft function, while three patients had delayed graft function requiring dialysis. Infectious complications occurring after the transplantation are summarized in table (2), 6 (21,4%) patients had septicemia, one case of peritonitis primary for urinary fistula and 2 patients had soft tissue abscesses. There were no cases of posttransplant lymphoproliferative disease or other malignancy. Two patients had symptomatic CMV disease. Conclusions: Low doses thymoglobulim may allow for more optimal induction and rejection therapy in pediatrics transplantation reduced infection complications and malignancy and no adverse events during infusion have made TMG an integral therapy for our renal transplant patients.